17 Biomarker interplay between CSF p-tau and 18F-PI-2620 PET in Alzheimer’s disease and 4R-tauopathy

ObjectivesReliable biomarkers for detecting different abnormal tau protein isoforms between neurodegenerative diseases are currently missing. Phosphorylated tau (p-tau) in the cerebrospinal fluid (CSF) is acknowledged as a 3/4R tau biomarker in AD but not in other tauopathies. The positron emission...

Full description

Saved in:
Bibliographic Details
Published in:BMJ neurology open 2023-08, Vol.5 (Suppl 1), p.A8-A8
Main Authors: Dilcher, Roxane, Wall, Stephan, Franzmeier, Nicolai, Katzdobler, Sabrina, Barthel, Henryk, Wagemann, Olivia, Palleis, Carla, Weidinger, Endy, Fietzek, Urban, Kurz, Carolin, Ferschmann, Christian, Scheifele, Maximilian, Eckenweber, Florian, Zaganjori, Mirlind, Gnörich, Johannes, Danek, Adrian, Bürger, Katharina, Janowitz, Daniel, Rauchmann, Boris-Stephan, Stöcklein, Sophia, Perneczky, Robert, Schöberl, Florian, Zwergal, Andreas, Höglinger, Günter, Bartenstein, Peter, Villemagne, Victor, Seibyl, John, Sabri, Osama, Levin, Johannes, Brendel, Matthias
Format: Article
Language:English
Subjects:
Biomarkers
Concurrent Session Abstracts
Disease
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesReliable biomarkers for detecting different abnormal tau protein isoforms between neurodegenerative diseases are currently missing. Phosphorylated tau (p-tau) in the cerebrospinal fluid (CSF) is acknowledged as a 3/4R tau biomarker in AD but not in other tauopathies. The positron emission tomography (PET) radiotracer 18F-PI-2620 has the potential to detect abnormal 3/4R-tau in patients with Alzheimer’s disease (AD) and 4R-tau in other tauopathies. This study investigates the interplay between tau-PET and CSF p-tau in AD and 4R-tauopathies.MethodsIn this cross-sectional analysis, 52 patients with AD, 54 patients with PSP/CBS, and 11 controls underwent lumbar puncture and 0–60 min dynamic 18F-PI-2620 PET scanning. Independent t-tests assessed group differences in standardized uptake value ratios for the 20–40min time window (SUVr20–40) and p-Tau. Multiple regression analyses tested the association between SUVr20–40 and p-tau and group interactions. ROC analyses evaluated biomarker performance in differentiating patient groups. Quantitative and voxel-wise analyses were performed with R, SPM, and VoxelStats, controlling for age and sex.ResultsPatients with AD showed elevated p-tau levels (p61 pg/ml) and SUVr20–40 in cortical regions, cingulate, insula, hippocampus, and amygdala (p
ISSN:2632-6140
DOI:10.1136/bmjno-2023-ANZAN.18